Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J-P Armand

Showing results (1-10 of 150) with videos related to

Pageof 15
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 15, 2000
Docetaxel (Taxotere) in the treatment of non-small cell lung cancer (NSCLC)--is there a role for a new chemotherapy programme?J P Armand
Seminars in Oncology|February 1, 1996
CPT-11: clinical experience in phase I studiesJ P Armand
Anti-Cancer Drugs|August 1, 1996
The clinical rationale for developing docetaxel (Taxotere)J P Armand
Bulletin Du Cancer|February 5, 1999
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas]C Couteau, J P Armand
Current Opinion in Oncology|July 1, 1994
Cardiotoxicity of chemotherapyM de Forni, J P Armand
European Journal of Cancer (Oxford, England : 1990)|August 19, 2004
Procarbazine in haematology: an old drug with a new life?M Massoud, J P Armand, V Ribrag
The Journal of Infusional Chemotherapy|July 1, 1996
CPT-11: the European clinical developmentC Terret, C Couteau, J P Armand
Drugs|December 29, 2000
Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapyE Raymond, S Faivre, J P Armand
Therapie|November 7, 1998
[Recommendations for the study of drug combination therapy for the treatment of AIDS and cancer. Round Table No 7 at Giens XIII]J P Armand, J Dormont, A Schwebig
Bulletin Du Cancer|February 5, 1999
[Irinotecan: various administration schedules, study of drug combinations, phase I experience]V Boige, E Raymond, J P Armand
Pageof 15

Showing results (1-10 of 150) with videos related to

Sort By:
Pageof 15
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 15, 2000
Docetaxel (Taxotere) in the treatment of non-small cell lung cancer (NSCLC)--is there a role for a new chemotherapy programme?J P Armand
Seminars in Oncology|February 1, 1996
CPT-11: clinical experience in phase I studiesJ P Armand
Anti-Cancer Drugs|August 1, 1996
The clinical rationale for developing docetaxel (Taxotere)J P Armand
Bulletin Du Cancer|February 5, 1999
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas]C Couteau, J P Armand
Current Opinion in Oncology|July 1, 1994
Cardiotoxicity of chemotherapyM de Forni, J P Armand
European Journal of Cancer (Oxford, England : 1990)|August 19, 2004
Procarbazine in haematology: an old drug with a new life?M Massoud, J P Armand, V Ribrag
The Journal of Infusional Chemotherapy|July 1, 1996
CPT-11: the European clinical developmentC Terret, C Couteau, J P Armand
Drugs|December 29, 2000
Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapyE Raymond, S Faivre, J P Armand
Therapie|November 7, 1998
[Recommendations for the study of drug combination therapy for the treatment of AIDS and cancer. Round Table No 7 at Giens XIII]J P Armand, J Dormont, A Schwebig
Bulletin Du Cancer|February 5, 1999
[Irinotecan: various administration schedules, study of drug combinations, phase I experience]V Boige, E Raymond, J P Armand
Pageof 15